



Inflation Reduction Act Impacts Cost Sharing for Medicare Part B Drugs

As of April 1, 2023, in accordance with §11101 and §11407 of the Inflation Reduction Act (IRA, P.L. 117-169):*

- Coinsurance for Part B rebatable drugs will be reduced if the drug’s price increases at a rate faster than the rate of inflation.
- Part B rebatable drugs may be in the following categories: chemotherapy administration services to include chemotherapy/radiation drugs or other drugs covered under Part B of original Medicare, as listed in §422.100(j)(1)(i).
- The list of Part B rebatable drugs, as well as the effective beneficiary coinsurance for those drugs, could change in each quarter. Applicable changes will be calculated based on quarterly pricing files published by CMS and posted to their website at <https://www.cms.gov/inflation-reduction-act-and-medicare/inflation-rebates-medicare>.

Split Billing and Modifiers:

- As of July 2023: For “from date of service” in July and later, bill a three-month supply of insulin with the JL modifier or a one-month supply of insulin with the JK modifier.
- HCPCS codes J1811 and J1813 have been added to the Insulin Modifiers.
- Claims that are submitted with J1811, J1813, and J1817, without a modifier, will be denied for a missing or invalid modifier.

From Date of Service	Modifier	Billing
July 2023 and later	JK or JL	Bill one-month or three-month supply with HCPCS codes J1811, J1813, and J1817

If you have any questions, please call Healthfirst Provider Services at **1-888-801-1660**, Monday to Friday, 8:30am–5:30pm.

www.cms.gov/newsroom/press-releases/inflation-reduction-act-tamps-down-prescription-drug-price-increases-above-inflation